Objectives This study investigates whether quantitative image analysis of pretreatment CT scans can predict volumetric response to chemotherapy for patients with colorectal liver metastases (CRLM). Methods Patients treated with chemotherapy for CRLM (hepatic artery infusion (HAI) combined with systemic or systemic alone) were included in the study. Patients were imaged at baseline and approximately 8 weeks after treatment. Response was measured as the percentage change in tumour volume from baseline. Quantitative imaging features were derived from the index hepatic tumour on pretreatment CT, and features statistically significant on univariate analysis were included in a linear regression model to predict volumetric response. The regression model was constructed from 70% of data, while 30% were reserved for testing. Test data were input into the trained model. Model performance was evaluated with mean absolute prediction error (MAPE) and R 2 . Clinicopatholologic factors were assessed for correlation with response. Results 157 patients were included, split into training (n = 110) and validation (n = 47) sets. MAPE from the multivariate linear regression model was 16.5% (R 2 = 0.774) and 21.5% in the training and validation sets, respectively. Stratified by HAI utilisation, MAPE in the validation set was 19.6% for HAI and 25.1% for systemic chemotherapy alone. Clinical factors associated with differences in median tumour response were treatment strategy, systemic chemotherapy regimen, age and KRAS mutation status (p < 0.05). Conclusion Quantitative imaging features extracted from pretreatment CT are promising predictors of volumetric response to chemotherapy in patients with CRLM. Pretreatment predictors of response have the potential to better select patients for specific therapies. Key Points • Colorectal liver metastases (CRLM) are downsized with chemotherapy but predicting the patients that will respond to chemotherapy is currently not possible.
Introduction
With nearly 140,000 new cases annually, colorectal cancer is the second leading cause of cancer-related mortality in the USA [1, 2] . The liver remains the most common site of metastasis and less than 5% of patients with colorectal liver metastases (CRLM) survive past 5 years if untreated [3] [4] [5] [6] . Combinations of systemic and regional therapies have been utilised to downsize CRLM, and in patients selected for hepatic resection, up to 20% can be cured [7, 8] . However, there is currently no method to predict response prior to chemotherapy administration for patients with CRLM. Identification of patients most or least likely to respond to a specific modality would allow a targeted approach to downsizing CRLM and tailored selection of treatments. In current clinical practice, response to chemotherapy is evaluated with radiographic criteria assessed on images obtained pre-and post-treatment (i.e. Response Evaluation Criteria in Solid Tumours, RECIST) [9] . Studies have explored imaging predictors of response with tumour morphology, early tumour shrinkage, perfusion CT and MRI, but these approaches require specialised sequences or analyse tumour change between two distinct points in time, after initiation of treatment [10] [11] [12] [13] [14] [15] [16] . Thus, validated pretreatment predictors of tumour response are needed to optimize the management of CRLM.
Since contrast-enhanced CT scans are routinely obtained for staging in colorectal cancer patients, they are widely available for image analysis and biomarker development [17] [18] [19] . Radiomics is an emerging field in which medical images are converted into mineable data by automated extraction of quantitative features that represent changes in radiographic enhancement patterns [20] . By applying radiomics to solid malignancies, imaging features can provide quantification of tumoral heterogeneity that is related to cell density, necrosis, fibrosis and haemorrhage [21] . Quantitative image analysis on CT scans has demonstrated an association between tumoral heterogeneity and survival in primary colorectal cancers and CRLM where patients with more heterogeneous tumours tended to have improved outcomes [21, 22] . On the basis of this finding, we sought to predict response to chemotherapy with quantitative image analysis of routine CT scans.
The main objective of our study is to evaluate whether imaging features from a single pretreatment CT scan can be used to predict volumetric response for patients receiving chemotherapy for CRLM.
Patients and methods

Patients
Approval from the institutional review board was obtained for retrospective analysis with waiver of informed consent. The study population was pooled from (A) two previously published prospective trials evaluating hepatic artery infusion (HAI) plus systemic chemotherapy for unresectable CRLM [23, 24] and (B) patients from a consecutive series from 2003 to 2007 previously reported on the use of neoadjuvant chemotherapy prior to hepatic resection [25] . Data Supplement 1 includes full inclusion and exclusion criteria: patients were excluded if they did not undergo a portal venous phase CT or receive the intended chemotherapy within each respective cohort. Inclusion in HAI trials required that patients have no evidence of extrahepatic metastases and be deemed to have unresectable CRLM by a multidisciplinary group of hepatobiliary surgeons and radiologists. In the second trial, the definition of unresectable CRLM was refined to include both technical (margin-negative resection would require resection of both portal veins, three hepatic veins, or the retrohepatic vena cava or resection would leave less than two adequately perfused and drained segments) or biologic (more than six metastases in a single lobe, with one lesion of at least 5 cm or at least six bilobar metastases) considerations.
Additional clinical and laboratory variables were collected from the electronic medical record and a prospectively maintained Hepatopancreatobiliary Service database within our institution. Synchronous disease was defined as hepatic metastases within 6 months of primary colon cancer diagnosis. Clinical risk score (CRS) has been previously reported and comprises five factors: more than one tumour, tumour greater than 5 cm, carcinoembryonic antigen (CEA) greater than 200 ng/mL, lymph node-positive primary and disease-free interval less than 12 months [26] . CRS was dichotomized into low (0-2) and high (3-5) risk groups.
Chemotherapy regimens
Cohort A was assembled from two previous clinical trials in which patients received standard HAI pump placement and infusion of floxuridine/dexamethasone (HAI FUDR) in combination with systemic chemotherapy [27] . Cohort A included patients that had received previous systemic chemotherapy and those that were treatment-naïve. All patients received HAI FUDR, but systemic chemotherapy varied by protocol, including irinotecan in all instances and oxaliplatin based on previous oxaliplatin utilisation [23, 24] . Bevacizumab was administered to approximately half of the patients in the latter protocol.
Patients from cohort B received first-line systemic neoadjuvant chemotherapy prior to hepatic resection. No patient in cohort B had received systemic chemotherapy within the previous year at the time of pretreatment imaging. Treatment regimens were not standardised and administered at the discretion of the primary medical oncologist. Various first-line combinations were employed, but included either oxaliplatin or irinotecan in all instances. Bevacizumab was selectively utilised.
For comparison of clinical factors associated with response, patients were grouped on the basis of the three overall treatment strategies included in this study: HAI in chemotherapy-naïve, HAI in previously treated patients and first-line systemic chemotherapy in treatment-naïve patients. Systemic chemotherapy regimen was defined as the specific combination of systemic treatment, irrespective of HAI utilisation, administered to the patient during the study interval.
Study design, CT imaging and statistical analysis
Chemotherapy response was measured as the percentage volumetric change of the index hepatic metastasis from baseline to the first follow-up CT scan obtained at approximately 8 weeks. The index hepatic metastasis was defined as the largest lesion that could be followed on repeat imaging in accordance with RECIST guidelines. Routine contrast-enhanced portal venous phase CT was used in all measurements. Multidetector CT scanner (Lightspeed 16 and VCT, GE Healthcare) was employed for abdominal imaging with main parameters: autoMA 220-380; noise index 12-14; rotation time 0.7-0.8 ms; scan delay 80 s. Images for selected patients were transferred from the picture archiving and communication system (PACS) to a workstation for image processing. The liver, tumours, vessels and bile ducts were semiautomatically segmented using Scout Liver (Pathfinder Technologies Inc.) and a 3D model generated. An image volume was created with the index tumour from the pre-and post-treatment scans.
Amongst all patients, clinicopathologic variables were assessed for an association with median percentage volumetric response and evaluated using the Mann-Whitney U test or Kruskal-Wallis test where appropriate. Differences in patient characteristics between training and validation sets were compared using Fisher exact test or chi-square test depending on the number of observations. A p value less than 0.05 was considered statistically significant and 95% confidence intervals were used. Analyses were conducted using SPSS statistical software (Version 22.0).
Quantitative image analysis
Quantitative image analysis was performed on the index tumour on baseline CT. A set of 272 imaging features, representing heterogeneity, were extracted using grey-level co-occurrence matrices (GLCM), run-length matrices (RLM), local binary patterns (LBP), fractal dimension (FD), intensity histogram (IH) and angle co-occurrence matrices (ACMs) [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] . Data Supplement 2 further describes feature extraction and image analysis, and Data Supplement 3 lists all imaging features included in this study.
Prediction model building & validation
Cohort A and B patients were combined and randomly split into training and validation sets, stratified by HAI to ensure proportional distribution of treatment strategies. Seventy percent of data (n = 110) were used to build the prediction model, and 30% of data (n = 47) were reserved for validation. On the basis of univariate analysis, quantitative imaging features associated with tumour response with p < 0.05 were initially selected. Highly correlated imaging features (correlation coefficient > 0.75) were removed from the feature set. In the situation of two highly correlated variables, only the imaging feature with the strongest association with response was retained. The remaining features and a variable denoting HAI utilisation were included in the final multivariate linear regression. Prediction error was reported as the mean absolute prediction error (MAPE), computed as the absolute difference between actual and predicted percent response, for both training and validation data. Figure 1 demonstrates workflow for image segmentation, feature extraction and selection, model building and evaluation.
Results
Patient characteristics
In total, 157 patients were pooled from cohort A (n = 103) and cohort B (n = 54) for quantitative image analysis to predict volumetric response. Clinicopathologic factors of all patients and the actual volumetric response are listed in Table 1 . Representative of the advanced stage and unresectable nature of many patients, the majority had bilobar disease (84%) and multiple lesions (90%). Overall, 43 patients (27%) were chemotherapy-naïve and received HAI and systemic therapy, 60 patients (38%) received HAI after prior systemic treatment and 54 patients (34%) received systemic chemotherapy only without previous treatment. Clinical factors related to volumetric response 
Feature selection results
Quantitative imaging features were evaluated for their association with response. On the basis of the univariate analysis and correlation coefficients, 30 features from the CT images in the training set were selected as inputs for the final multivariate regression model (Table 2 ). In Fig. 2 , one of the most predictive imaging features, called entropy, was chosen to illustrate CT appearance differences among patients with varying volumetric responses. Entropy is a commonly evaluated feature in the literature that describes pixel randomness within a greyscale image [22] . Higher entropy values, representing increased heterogeneity, were associated with increased volumetric response in CRLM [43, 44] . Representative CT images, 24 × 24 pixel patches from the index tumour, entropy values and responses are depicted in Fig. 2 . Entropy was calculated using the entire tumour volume.
Creation and evaluation of prediction model
Combining the selected features from the training set, a multivariate linear regression was constructed for percentage tumour response. This prediction model was then separately tested with the same features extracted from the CT images in the validation cohort. The training and validation results of the regression models are listed in Table 3 . MAPE represents the mean difference between the predicted responses from the model versus the actual radiographic responses. The MAPE for the training set was 16.5% and that for the validation set was 21.5%. R 2 value for the regression was 0.77. Figure 3a , b include scatterplots of predicted versus actual response for training and validation sets. A waterfall plot of prediction error for all training as well as test cases is provided in Fig. 3c to illustrate the distribution of error over different samples. A secondary analysis of the patients in the validation set, stratified by HAI utilisation, demonstrated a MAPE of 19.5% (n = 31) for those patients with HAI chemotherapy and 25.1% (n = 16) for patients with systemic chemotherapy only.
Discussion
For patients with CRLM treated with chemotherapy, pretreatment CT image analysis contains predictive information for early response as measured by volumetric change. The magnitude of response of CRLM was also associated with overall treatment strategy, the type of systemic chemotherapy, age and KRAS mutation status. This is the first study to predict volumetric treatment response using tumour-derived quantitative features of heterogeneity from routinely acquired pretreatment CT scans. These results represent a step in the development of radiomics for clinical applications to improve selection of specific treatments for patients with CRLM.
Predicting response based on tumour enhancement patterns on a pretreatment CT has clinical utility for all patients with CRLM. Radiographic response to chemotherapy will have different implications based on individual clinical scenario, but a pretreatment prediction would be a tool for any oncologist or surgeon who treats patients with CRLM. Thus, we included patients with initially unresectable and resectable metastatic disease, distributed evenly between the 70/30 training and validation sets. In the validation set, we observed a MAPE of 21.5%, which represents the mean error between the predicted response and the actual radiographic response. To determine whether the achieved error (21.5%) was clinically acceptable, the tumour was modelled as a sphere. The majority of the volume of a sphere lies at the surface. Considering the tumour as a sphere, the error in the radius is less than 8%. This means that in a tumour with a change in radius of 10 mm, we would predict a tumour radius change of 9.2 mm or 10.7 mm. The error is therefore within the bounds of CT scanner resolution and segmentation accuracy. As a true radiographic prediction from one distinct time point, the model displays acceptable error with a high R 2 value. At present, this model may have the most utility at the extremes of response. Pretreatment identification of patients with a very favourable or unfavourable response to treatment would assist clinical decision-making. Compared to previous studies, our approach addresses the limitation of using specialised imaging techniques or multiple imaging time points to predict response in CRLM. Kim et al. identified changes in CT perfusion parameters as predictors of early tumour response using the pretreatment and first posttreatment scan [13] . Early tumour shrinkage (ETS) of target lesions is also associated with outcomes, but both of these techniques give prognostic information only after the first cycle of chemotherapy [11] . Other groups have investigated baseline dynamic contrast-enhanced MRI to predict treatment outcome, but this requires imaging studies not performed in routine staging of metastatic colorectal cancer [15] . Our results demonstrate that quantitative image analysis of one routinely acquired pretreatment CT scan holds information predictive of early response. This process may be automated in the future and, if validated, more widely applicable to general practice owing to the ubiquitous use of contrast-enhanced CT.
Similar to radiographic CRLM morphology, our group hypothesised that there is a relationship between tumour heterogeneity on quantitative imaging and response [10] . The Hounsfield unit (HU) is a standard measure in CT scanning that reflects the overall atomic density of soft tissues being imaged. The density of CRLM will vary across patients by their differential uptake of iodinated contrast on contrastenhanced CT. While each imaging feature of heterogeneity is weighted differently, 30 individual features served as inputs for the regression model. Entropy, a measure of the randomness of pixel intensity values within a region of interest, was one of the selected features for the model. Entropy is discriminatory in the literature and also can be well described in radiographic terms. For illustration purposes, entropy and representative pre-and post-treatment CT scans are shown in Fig.  2 . Entropy showed an association between higher values and increased response. Heterogeneous tumours, with higher entropy, may exhibit improved vascular delivery of chemotherapy and viable tumour tissue. Heterogeneous tumours have already been associated with improved survival [22] , but our results support the hypothesis that tumours with increased heterogeneity also have greater potential for volumetric response to chemotherapy.
Currently, HAI chemotherapy is restricted to a small group of high-volume centres. HAI has been shown to be most efficient when used as first-line therapy [45] . In our study, the greatest median response was observed in patients treated with HAI and systemic chemotherapy who were chemotherapynaïve. Prior chemotherapy had been administered to a subset of HAI patients (n = 60) in this analysis. Decreased volumetric response was expected in this group on the basis of published rates of response with HAI in patients with prior chemotherapy versus chemotherapy-naïve [24, 46] . Nonetheless, a median volumetric response of 61% demonstrates the impact of HAI, especially in a previously treated population. For this reason, HAI utilisation was included as a variable in the prediction model. An accurate pretreatment, radiographic predictor of response would allow better patient selection for HAI therapy. The potential clinical benefit is twofold, avoiding HAI pump placement in patients with predicted marginal benefit, but also increasing utilisation in patients with predictably favourable responses. At present, HAI pump chemotherapy is an expensive treatment with potential complications that demands close patient and physician involvement and commitment [47] . Developing predictors of response will aid patients in making informed decisions regarding their choice of specific treatments.
Since the use of HAI remains limited, we also included patients who were treated with systemic chemotherapy alone. In previous systemic chemotherapy studies, partial response was observed in 28-72% of patients [7] . Our results demonstrate that the median volumetric change was -66% in this subset, but the results are spread over a wide range (-100% to + 193%). As first-line systemic chemotherapy in previously untreated patients, these findings are not surprising. Nonetheless, this study was not designed to directly compare different treatment strategies or make chemotherapy recommendations; rather, the project was aimed at building a prediction model based on CT enhancement patterns of pretreatment CRLM, regardless of therapy. By incorporating patients in the training set with a wide range of treatments and responses, the prediction model was created with image analysis of CT scans from a population that reflects the variation encountered in actual clinical practice.
This study has several limitations. First, this was a retrospective study and these results are limited to patients at a tertiary centre with high-volume HAI pump placement and hepatic resections. Second, this study only analysed the index tumour. In CRLM, individual hepatic metastases may potentially show different volumetric responses to chemotherapy. However, given the varied number of hepatic metastases between patients, considerations regarding statistical analysis and the regression model influenced our decision to include only the index hepatic tumour. Furthermore, other clinical variables, such as KRAS [48] . Since KRAS mutation status may not be known at the time of CRLM diagnosis, it was not included in the prediction model. As next-generation sequencing improves, these results indicate the future potential to combine both pretreatment CT imaging and genomic variables to predict response with a high degree of accuracy. Even with these limitations, this study linked quantitative imaging features with clinically applicable data from prospective trials and a retrospective surgical series. The next steps in development include validation of these methods with a separate data set from another institution or ideally a prospective trial of quantitative image analysis and response. Further prospective investigations accounting for type and delivery of chemotherapy may allow improved prediction models with the potential to better select patients for specific treatments.
Conclusion
This study demonstrates that quantitative imaging features extracted from pretreatment CT are promising predictors of volumetric response to chemotherapy in patients with CRLM. Prospective validation is required prior to using these novel imaging markers in the clinical setting, but should be pursued. Pretreatment prediction of response to chemotherapy has the potential to better select patients for individualised treatments.
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